Improving predictions of the risk of resistance development against new and old antibiotics

Clinical Microbiology and Infection

Volumn 21, Issue 10, 2015, Pages 894-898

  Andersson, D I ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antibiotic resistance; Fitness; Horizontal gene transfer; Mutation rate; Prediction

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; HORIZONTAL GENE TRANSFER; HUMAN; METAGENOME; MUTANT; MUTATION RATE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; BACTERIUM; DRUG DEVELOPMENT; DRUG EFFECTS; PROCEDURES;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; RISK ASSESSMENT;

EID: 84942191993     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.05.012     Document Type: Review

References (37)

1. Ling L.L., Schneider T., Peoples A.J., Spoering A.L., Engels I., Conlon B.P., et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015, 517(7535):455-459.
2. Martinez J.L., Baquero F., Andersson D.I. Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics. Curr Opin Pharmacol 2011, 11:439-445.
3. Dong Y., Zhao X., Domagala J., Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999, 43:1756-1758.
4. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 2003, 52:11-17.
5. Wright G.D. Antibiotic resistance in the environment: a link to the clinic?. Curr Opin Microbiol 2010, 13:589-594.
6. Perry J.A., Westman E.L., Wright G.D. The antibiotic resistome: what's new?. Curr Opin Microbiol 2014, 21:45-50.
7. Poirel L., Kampfer P., Nordmann P. Chromosome-encoded Ambler class A beta-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2002, 46:4038-4040.
8. Humeniuk C., Arlet G., Gautier V., Grimont P., Labia R., Philippon A. Beta-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types. Antimicrob Agents Chemother 2002, 46:3045-3049.
9. Decousser J.W., Poirel L., Nordmann P. Characterization of a chromosomally encoded extended-spectrum class A beta-lactamase from Kluyvera cryocrescens. Antimicrob Agents Chemother 2001, 45:3595-3598.
10. Poirel L., Lartigue M.F., Decousser J.W., Nordmann P. ISEcp1B-mediated transposition of blaCTX-M in Escherichia coli. Antimicrob Agents Chemother 2005, 49:447-450.
11. Poirel L., Rodriguez-Martinez J.M., Mammeri H., Liard A., Nordmann P. Origin of plasmid-mediated quinolone resistance determinant QnrA. Antimicrob Agents Chemother 2005, 49:3523-3525.
12. Park B.H., Levy S.B. The cryptic tetracycline resistance determinant on Tn4400 mediates tetracycline degradation as well as tetracycline efflux. Antimicrob Agents Chemother 1988, 32:1797-1800.
13. Speer B.S., Salyers A.A. Characterization of a novel tetracycline resistance that functions only in aerobically grown Escherichia coli. J Bacteriol 1988, 170:1423-1429.
14. Leski T.A., Bangura U., Jimmy D.H., Ansumana R., Lizewski S.E., Stenger D.A., et al. Multidrug-resistant tet(X)-containing hospital isolates in Sierra Leone. Int J Antimicrob Agents 2013, 42:83-86.
15. Locke J.B., Hilgers M., Shaw K.J. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 2009, 53:5265-5274.
16. Hughes D., Andersson D.I. Carbon starvation of Salmonella typhimurium does not cause a general increase of mutation rates. J Bacteriol 1997, 179:6688-6691.
17. Thulin E., Sundqvist M., Andersson D.I. Amdinocillin (mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli. Antimicrob Agents Chemother 2015, 59:1718-1727.
18. Kahlmeter G. Eco.Sens. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003, 51:69-76.
19. Kahlmeter G., Poulsen H.O. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012, 39:45-51.
20. STREPTOMYCIN treatment of pulmonary tuberculosis. Br Med J 1948, 2(4582):769-782.
21. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001, 357(9263):1179.
22. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001, 358(9277):207-208.
23. Kass E.H. Bacteriuria and the diagnosis of infections of the urinary tract; with observations on the use of methionine as a urinary antiseptic. AMA Arch Intern Med 1957, 100:709-714.
24. Smith M.R., Wood W.B. An experimental analysis of the curative action of penicillin in acute bacterial infections. III. The effect of suppuration upon the antibacterial action of the drug. J Exp Med 1956, 103:509-522.
25. Palaci M., Dietze R., Hadad D.J., Ribeiro F.K., Peres R.L., Vinhas S.A., et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol 2007, 45:4064-4066.
26. Canetti G. Dynamic aspects of the pathology and bacteriology of tuberculous lesions. Am Rev Tuberc 1956, 74:13-21. discussion, 2-7.
27. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965, 92:687-703.
28. Bingen E., Lambert-Zechovsky N., Mariani-Kurkdjian P., Doit C., Aujard Y., Fournerie F., et al. Bacterial counts in cerebrospinal fluid of children with meningitis. Eur J Clin Microbiol Infect Dis 1990, 9:278-281.
29. Feldman W.E. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J Pediatr 1976, 88:549-552.
30. Gordon D.M., Riley M.A. A theoretical and experimental analysis of bacterial growth in the bladder. Mol Microbiol 1992, 6:555-562.
31. Nilsson A.I., Berg O.G., Aspevall O., Kahlmeter G., Andersson D.I. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003, 47:2850-2858.
32. Sandegren L., Lindqvist A., Kahlmeter G., Andersson D.I. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother 2008, 62:495-503.
33. Roussos N., Karageorgopoulos D.E., Samonis G., Falagas M.E. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009, 34:506-515.
34. Popovic M., Steinort D., Pillai S., Joukhadar C. Fosfomycin: an old, new friend?. Eur J Clin Microbiol Infect Dis 2010, 29:127-142.
35. Sander P., Springer B., Prammananan T., Sturmfels A., Kappler M., Pletschette M., et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002, 46:1204-1211.
36. Lofton H., Anwar N., Rhen M., Andersson D.I. Fitness of Salmonella mutants resistant to antimicrobial peptides. J Antimicrob Chemother 2015, 70:432-440.
37. Andersson D.I., Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat Rev Microbiol 2010, 8:260-271.